Lack of Evidence for Parvovirus B19 Viraemia in Children With Chronic Neutropenia

Hartman, Kip R.; Brown, Kevin E.; Green, Spencer W.; Young, Neal S.

doi:10.1111/j.1365-2141.1994.tb05136.x

Cited by 16 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hartman et al . used dot‐blot to detect B19 DNA in serum of patients with chronic neutropenia of childhood ( n = 27), chronic neutropenia of young adults ( n = 7), immune thrombocytopenia ( n = 9), and other diagnoses ( n = 13). They found that only one patient was positive for serum B19 DNA; a 20 year old woman with chronic neutropenia following bone marrow transplant who was treated with intravenous immunoglobulin (IVIG) with improvement.…”

Section: Introductionmentioning

confidence: 99%

A review of blood diseases and cytopenias associated with human parvovirus B19 infection

Kerr

2015

Reviews in Medical Virology

View full text Add to dashboard Cite

Parvovirus B19 is a single-stranded DNA virus which preferentially targets the erythroblast resulting in red cell aplasia, which is temporary in immunocompetent persons. Since the discovery of B19 virus in 1975, a wide variety of blood diseases and cytopenias affecting several blood cell lineages have been documented during or following B19 infection. These include cytopenias affecting the erythroid, megakaryoblastoid, myeloid and lymphoid lineages, as well as a variety of bicytopenias, pancytopenia, bone marrow necrosis / fat embolism syndrome, myelodysplastic syndrome, leucoerythroblastopenia, and hemophagocytic lymphohistiocytosis. B19 infection may also complicate and precede the course of acute leukemia, the significance of which remains to be determined. This review describes the current state of knowledge of the abnormalities of individual blood cell lineages encountered during parvovirus B19 infection, over the almost 40 years since its discovery, and reveals some very interesting themes, which improve our understanding of the pathogenesis of B19 infection with particular reference to the bone marrow.

show abstract

Section: Introductionmentioning

confidence: 99%

A review of blood diseases and cytopenias associated with human parvovirus B19 infection

Kerr

2015

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Because B19 is a non–lipid‐enveloped viral pathogen, inactivation methods like solvent/detergent treatment are ineffective for reduction of virus concentration in plasma. Most infections occur in childhood and result in a mild rash and formation of protective antibodies 7‐13 . Infection normally results in seroconversion with neutralizing immunoglobulin G (IgG) antibodies affording life‐long protection from reinfection in most cases 14 .…”

mentioning

confidence: 99%

“…Most infections occur in childhood and result in a mild rash and formation of protective antibodies. [7][8][9][10][11][12][13] Infection normally results in seroconversion with neutralizing immunoglobulin G (IgG) antibodies affording lifelong protection from reinfection in most cases. 14 Chronic infection, however, may be associated with a poor antibody response.…”

mentioning

confidence: 99%

Blood donor screening for parvovirus B19 in Germany and Austria

et al. 2007

View full text Add to dashboard Cite

The release of B19 DNA-positive blood products with a concentration of less than 105 IU per mL is thought to be safe due to the high level of neutralizing VP2 antibodies and is currently examined in a donor recipient infectivity study. In contrast, blood products with a high B19 DNA concentration (> or =10(5) IU/mL), some of which did not contain neutralizing antibodies, were discarded to protect at risk individuals.

show abstract

“…B19 infection has also been implicated as a causative agent for vasculitis, myocarditis, glomerulone phritis and transient erythroblastopenia [55] and as a pos sible cause of chronic childhood neutropenia [70] and haemophagocytosis with resultant pancytopenia [71,72], al though the latter is debated [73]. Recent reports provide stronger evidence for a role in paediatric liver dysfunction ised to the liver [80].…”

Section: Introductionmentioning

confidence: 99%

Human Parvovirus B19 and Blood Products

Prowse¹,

Ludlam²,

Yap³

1997

Vox Sanguinis

View full text Add to dashboard Cite

Background and objectives: Human B19 parvovirus (B19), identified in 1975, was only recognised as the causative agent of fifth disease in 1983. The incidence of viraemia is low, around 1 in 1,000, but is sufficient to ensure that most plasma pools for fractionation contain some virus. While infection usually occurs in childhood and is benign, chronic infection sometimes occurs and may be of concern in certain patient groups. Materials and methods: This review is based on a meeting held in March 1995, and addresses recent concerns regarding the potential transmission of B19 infection by pooled plasma products. Results: Recent data on the pathophysiology and assay of this virus are summarised along with possible approaches to donor screening, product screening, and virus removal. Only five cases of symptomatic infection have been reported in persons with haemophilia, but no technology for vims removal is established, and infection may be of concern in pregnant women, and in patients with enhanced red cell turnover or who are immunosuppressed, including those infected with human immunodeficiency vims, but only rarely in immunocompetent patients. Conclusions: For the future, well-validated assays relevant to vims infectivity are required if blood donations, plasma pools, or plasma products are to be screened, and an in-process vims inactivation step for B19 would be highly desirable. In the interim, non-plasma or recombinant products or a selective transfusion policy might be used in patient groups in which B19 infection is of particular concern. Further clinical data on the prognosis and impact of B19 infection are needed to justify both such policies and the future adoption of new technologies designed to reduce any excess B19 infectivity arising from transfused products.

show abstract

Lack of Evidence for Parvovirus B19 Viraemia in Children With Chronic Neutropenia

Cited by 16 publications

References 5 publications

A review of blood diseases and cytopenias associated with human parvovirus B19 infection

A review of blood diseases and cytopenias associated with human parvovirus B19 infection

Blood donor screening for parvovirus B19 in Germany and Austria

Human Parvovirus B19 and Blood Products

Contact Info

Product

Resources

About